[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"insulin-resistance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:insulin-resistance":674},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,97,0,25,[9,44,70,83,114,142,171,221,251,276,296,324,343,352,379,404,434,460,485,512,542,563,602,621,644],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053897",false,"NCT06007404","Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents","The Role of Circulating Meta-Inflammatory Monocytes in Adolescent Insulin Resistance","Inclusion Criteria:\n\n* Between 14 and 18 years of age\n* Tanner stage 4 or 5 (mature adult stage of puberty)\n* Normal weight (BMI ≥ 5th percentile \\& \\\u003C 85th percentile), overweight (BMI \\> 86th percentile) \\& \\\u003C 94th percentile), obese weight (BMI percentile ≥ 95th percentile), and\u002For pre-diabetes (HbA1c \\> 5.7%)\n* For Type 2 Diabetes cohort, diagnosis of Type 2 Diabetes\n\nExclusion Criteria:\n\n* Currently pregnant\n* Use medications known to affect glucose metabolism (immunosuppressive medications, cancer medications, or high dose steroids), unless prescribed for Type 2 Diabetes management\n* Prior diagnosis of autoimmune disease, cancer, or a cognitive or perceptual disability that would inhibit following directions of study staff\n* Allergies or intolerance to milk, soy, or palm oil",true,"ALL","14 Years","18 Years",{"count":21,"type":22},175,"ESTIMATED","OBSERVATIONAL","This research study collects health-related information and blood samples to better understand how body composition, lifestyle habits, and diet influence meta-inflammatory monocytes (MiMos) in adolescents. The hypothesis of this study is that adolescents at risk for metabolic disease have enhanced MiMo related activities leading to insulin resistance.",[26,27,28,29,30],"Type 2 Diabetes","Insulin Resistance","Obesity","Metabolic Disease","PreDiabetes","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2023-09-06",{"date":39,"type":22},"2027-09",{"name":41,"class":42},"University of Michigan","OTHER",1,{"id":45,"slug":4,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100053438","NCT05713799","Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity","Phase II Trial of the Combination of Alpha-lipoic Acid and Mirabegron in Women and in Men With Obesity","* INCLUSION CRITERIA\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Adults 18 to 65 years of age\n2. BMI greater than or equal to 30 kg\u002Fm\\^2 and less than or equal to 45 kg\u002Fm\\^2\n\nEXCLUSION CRITERIA\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Hypersensitivity and associated allergic reactions to mirabegron or alpha-lipoic acid (or similar drug substances or components).\n2. Abnormal bladder function, diagnosis of bladder outlet obstruction, urgency, and urinary frequency or use of antimuscarinic medication to treat overactive bladder (OAB).\n3. Type 1 diabetes mellitus; type 2 diabetes mellitus; or any person taking exogenous insulin therapy or any medication that is a hypoglycemic agent. (type 1 or Type 2 Diabetes mellitus, fasting serum glucose \\>125 mg\u002FdL, and\u002For an HbA1c test \\>6.5%).\n4. Elevated resting blood pressure \\>140\u002F90 mmHg.\n5. Individuals with eGFR \\\u003C60 ml\u002Fmin\u002F1.72 m\\^2 and a urinary albumin\u002Fcreatinine ratio UACR\\>300 mg\u002Fg.\n6. Hypo- or hyper-thyroid disease (TSH \\>5.0, or \\\u003C0.4 MIU\u002FL) that is controlled for less than one year or someone currently taking thyroid hormone replacement.\n7. Anemia, defined by hemoglobin \\\u003C11.5 g\u002FdL (females) or \\\u003C13.5 g\u002FdL (males); sickle cell anemia or other blood disorders; and\u002For wound healing problems.\n8. Cardiovascular disease, cardiac arrhythmias, orthostasis, unstable vasomotor system, or renal impairment.\n9. A clinically significant abnormal ECG and\u002For QTc interval above normal\n10. Moderate hepatic impairment (Child-Pugh Class B) or above\n11. Elevated liver enzymes \\>75 U\u002FL (ALT or AST)\n12. Recent history in last 4 weeks of any local or systemic infectious disease with fever or requiring antibiotics\n13. Pregnancy, childbirth within the last year, or breastfeeding in the past 12 months.\n14. Individuals that have been on a very low-calorie diet (\\\u003C800 kcal\u002Fd), self-reported weight loss \\>5% in the preceding six months, or those taking weight loss medications.\n15. History of seizure disorder.\n16. Addiction to alcohol or substances of abuse within the last 5 years.\n17. Self-reported current alcohol consumption of more than 2 servings of alcohol per day.\n18. Self-reported current use of nicotine and\u002For tobacco products.\n19. Current use of any drugs known to:\n\n    1. Have major drug-drug interactions with mirabegron or alpha-lipoic acid\n    2. Be CYP2D6 substrates\n    3. Prolong QT interval\n    4. Alter glucose metabolism or cause insulin resistance (in last six months)\n    5. Treat diabetes mellitus\n    6. Treat hypertension\n    7. Be drugs of abuse\n20. Inability to provide informed consent.\n21. Unwilling or unable to eat metabolic meals, as determined by dietitian consult.\n22. Individuals with significant medical comorbidities or other factors that would render the individual s participation unsafe or affect the outcome of the study as assessed by the investigator.","65 Years",{"count":52,"type":22},60,"INTERVENTIONAL",[55],"PHASE2","Background:\n\nObesity and related illnesses cause at least 2.8 million deaths each year worldwide. Few treatments exist for obesity that are safe and widely available. A study drug (mirabegron \\[MG\\]) combined with a supplement (alpha-lipoic acid \\[ALA\\]) may help.\n\nObjective:\n\nTo learn how MG and ALA can help the body process food.\n\nEligibility:\n\nPeople aged 18 to 65 years with a body mass index between 30 and 45 kg\u002Fm2.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam. They will have blood and urine tests and a test of their heart function. They will speak with a dietician.\n\nThe study has two phases. Each phase begins with a 2-day stay in the clinic; then the participant will take the study drugs at home for about 4 weeks, followed by another 2-day stay in the clinic. They will also have outpatient visits about 2 weeks after each clinic stay.\n\nDuring the clinic stays, participants will undergo many tests:\n\nThey will have a plastic tube (catheter) inserted into a vein in each arm. These will be used to draw blood and to infuse glucose (sugar) and insulin.\n\nThey will have imaging scans.\n\nThey will have a clear hard plastic shield placed over their head to measure oxygen and carbon dioxide as they breathe.\n\nParticipants will take the study drugs at home. Both MG and ALA are taken by mouth with water. During one phase, participants will take MG plus a placebo. A placebo looks like the study drug but doesn t contain medicine....",[27,28],[28,59,27,60],"Insulin Sensitivity","Placebo","NOT_YET_RECRUITING",{"date":34,"type":35},{"date":64,"type":22},"2026-07-16",{"date":66,"type":22},"2030-03-01",{"name":68,"class":69},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",{"id":71,"slug":4,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":50,"enrollmentInfo":72,"targetDuration":4,"studyType":53,"phases":73,"briefSummary":56,"conditions":74,"keywords":75,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":82,"locationsCount":43},"100494101",{"count":52,"type":22},[55],[27,28],[28,59,27,60],"2026-07-01",{"date":78,"type":35},"2026-07-02",{"date":80,"type":22},"2026-07-07",{"date":66,"type":22},{"name":68,"class":69},{"id":84,"slug":4,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":16,"sex":17,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":53,"phases":94,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":43},"100642973","NCT07624500","Food and Metabolism Study","Effects of Avocado on Triglyceride Metabolism in Individuals With Insulin Resistance","FAM","Inclusion Criteria:\n\n* Men or women, 40-70 years of age.\n* Fasting triglycerides (TG) \\>115 mg\u002FdL.\n* Insulin resistance as measured by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) \\>2.5.\n* Able to provide informed consent.\n* Able to comply with and perform the procedures requested by the protocol, specifically eat all the meals and snacks provided by the study which will be almost all your food (\\~ 80% of calories per day).\n* Able to come to the clinic up to 6 times during the study.\n* Able to maintain usual physical activity pattern.\n* Able to avoid\u002Fabstain from alcohol and vigorous physical activity for 24 hours prior to and during study visit.\n\nExclusion Criteria:\n\n* Men and women with known or suspected intolerance, allergies or hypersensitivity to study foods or interventions.\n* Fasting blood sugar ≥125 mg\u002FdL. Men and women with blood pressure \\>160 mmHg (systolic) \u002F 100 mmHg (diastolic) at the screening visit.\n* Men and women with history of diabetes cardiovascular events, respiratory, renal, gastrointestinal, hepatic or eye disease or surgery- within a year.\n* Men and women who have or had cancer other than non-melanoma skin cancer in the past 5 years.\n* Men and women taking over the counter or prescription medications or dietary supplements that may interfere with study procedures or endpoints.\n* Men and women who are on a specialized diet (vegan, vegetarian, keto, etc.). - - Men and women who consume nuts or peanuts daily or most days of the week.\n* Men and women who are not weight stable (+\u002F-10lbs in previous 2 months). Men and women who have excessive use of drugs or alcohol (ie., addictions) within the past 2 years.\n* Men and women with documented physical or mental disease\u002Fcondition, which might limit participation in or completion of the study or, that, in the opinion of the investigator, could interfere with the interpretation of the study results.\n* Women who are known to be pregnant or who are intending to become pregnant over the course of the study.\n* Women who are lactating.\n* Major trauma or a surgical event within 2 months (or longer depending on trauma or event) and after consultation with PI. Has used antibiotics within the previous 2 months.\n* History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional.\n* Excessive coffee and tea consumers (\\> 4 cups\u002Fd).\n* Donated blood within the last 3 months.\n* Women who are taking an unstable dose and brand of hormonal contraceptives and\u002For a stable dose and brand for less than 6 months.\n* Unusual working hours (working overnight).","40 Years","70 Years",{"count":93,"type":22},82,[95],"NA","In this study, Investigators are interested in looking at the influence of eating avocados regularly, which are rich in healthy fats, fibers, and unique carbohydrates, on triglyceride and glucose metabolism in people with prediabetes and insulin resistance.",[98,27,99,100],"Prediabetes","Triglycerides","Lipids Metabolism",[99,102,103,104],"Insulin resistance","Glucose metabolism","Lipids metabolism","2026-06-29",{"date":76,"type":35},{"date":108,"type":35},"2026-06-03",{"date":110,"type":22},"2027-12-31",{"name":112,"class":113},"Clinical Nutrition Research Center, Illinois Institute of Technology","INDUSTRY",{"id":115,"slug":4,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":53,"phases":123,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":137,"leadSponsor":139,"locationsCount":141},"100639897","NCT07599072","PREdiabetes GLycemic Impact and Data Evaluation","Evaluation of the Impact of Continuous Glucose Monitoring (CGM) Systems on Glycemic Control in People With Prediabetes: Postmarketing Clinical Study","PRE-GLIDE","Inclusion Criteria:\n\n* Age of 18 years and older.\n* Presence of prediabetes diagnosed according to criteria of the American Diabetes Association\n* Persons who treated with diet and exercise alone or metformin on a stabilized dose for at least 3 months before the study;\n* Ability to comply with protocol requirements and maintain a patient diary.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Presence of type 1 or type 2 diabetes;\n* Decompensated liver or kidney diseases (GFR \\\u003C 45 ml\u002Fmin\u002F1. 73 m²);\n* Active cardiovascular diseases within 12 months of Visit 1, such as myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, or angioplasty; or are expected to require coronary artery bypass surgery or angioplasty during the course of the study;\n* Endocrine disorders (e.g., Itsenko-Cushing syndrome, acromegaly) that affect glycemia;\n* Pregnancy or lactation;\n* Mental or cognitive impairments that would interfere with study participation;\n* Daily use of any form of steroid medication (oral, inhaled, injected) within the last 3 months;\n* Recent use of any CGM within the last 12 months;\n* Known allergy to sensor materials;\n* Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant;\n* Participation in another clinical study within the last 3 months.",{"count":122,"type":22},80,[95],"This prospective, randomized controlled trial evaluates whether real-time continuous glucose monitoring (CGM) improves glycemic control and lifestyle adherence in adults with prediabetes compared to conventional self-monitoring methods over a 3-month period. By analyzing metabolic markers and behavioral data, the study aims to determine the effectiveness of 24-hour monitoring as a personalized tool that increases patient adherence to lifestyle changes compared to conventional SMBG methods.",[126,127,27],"Pre Diabetic","Obesity & Overweight",[129,130,131,132,133],"prediabetes","obesity","continuous glucose monitoring","insulin resistance","traditional glycemia self-monitoring",{"date":135,"type":35},"2026-06-30",{"date":76,"type":22},{"date":138,"type":22},"2027-06-30",{"name":140,"class":42},"Nazarii Kobyliak",3,{"id":143,"slug":4,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":153,"conditions":154,"keywords":159,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":43},"100645093","NCT07678736","The Muscle Monitor: Early Skeletal Muscle Indicators of Insulin Resistance and Cardiometabolic Risk","The Muscle Phenotype and Cardiometabolic Health Monitoring Project","MUSCLE MONITOR","Inclusion Criteria:\n\n* Sex: Males and females\n* Age: 20-30 years\n* BMI \\\u003C35\n* Healthy (no diagnosed chronic disease)\n\nExclusion Criteria:\n\n* Chronic disease deemed to affect study outcomes\n* Disease that increase haemorrhage risk\n* Daily intake of medication that could confound study outcomes\n* Regular smokers\n* Active pregnancy\n* Immobilization (inactivity due to injury or illness, e.g. cast or brace) for more than a week in the month prior to the study or for more than 4 weeks in the past 6 months prior to the study\n* Very high structured physical exercise level (\\>10 h\u002Fweek).\n* Participants not willing to adhere to standardized meal prescriptions included in the study protocols will also be excluded (due to e.g. allergies or specific dietary preferences)","20 Years","30 Years",{"count":152,"type":22},250,"Insulin resistance is an early etiological factor in the development of type-2 diabetes (T2D), which constitutes a large societal health burden with an expected additional rise in the years to come.\n\nSkeletal muscle is the body's largest lean tissue mass and the major site of glucose disposal in response to insulin stimulation. Prior studies have suggested that a fast skeletal muscle phenotype, including a predominant fast muscle fiber composition, reduced capillary density, low fat oxidation and muscle oxidative capacity may be implicated in insulin resistance and TD2 development. However, key questions pertain in relation to the cause and effect of these relationships as well as the interaction with potential confounders and effect-modifiers including life-style factors (e.g. diet and physical activity levels) and general participant characteristics (e.g. body composition and training status).\n\nIn the present project, we therefore aim to derive muscle fiber type and extensively map the proteomic signature of the early stages of insulin resistance in a large cross-sectional study using a young and apparently healthy cohort prior to T2D development, including a thorough participant characterization. We will recruit \\~250 participants (men and women) in the age of 20-30 years and conduct extensive phenotyping and tissue sampling across one laboratory-based test day and a scan visit, as well as measurements of physical activity level and glucose handling in free-living conditions with wearable sensors.\n\nThe study has a longitudinal aspect as participants will be re-invited at 5-year intervals for up to 20 years to delineate the trajectory of metabolic health in relation to muscle phenotype measures.\n\nThe results of the project are expected to lead to significant advancements in our understanding of the importance of muscle phenotype for early-stage insulin resistance and metabolic health trajectories. Such understanding has potentially important clinical implications, as it can open new avenues for targeted interventions and individualized early preventive strategies to counter or delay the progression of insulin resistance and associated metabolic and cardiovascular disorders.",[27,155,156,157,158],"Insulin Resistance and Type 2 Diabetes","Cardiometabolic Risk Factors","Physical Activity","Muscle Fiber Type",[160,161,162],"Insulin sensitivity","Skeletal muscle","Physical activity","2026-06-24",{"date":76,"type":35},{"date":166,"type":35},"2025-05-19",{"date":168,"type":22},"2046-12-31",{"name":170,"class":42},"University Ghent",{"id":172,"slug":4,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":53,"phases":179,"briefSummary":180,"conditions":181,"keywords":197,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":220},"100526751","NCT06138821","Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial","Effect of Endoscopic Sleeve Gastroplasty on Patients With Obesity and Concomitant Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Multicenter, Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 (male or female)\n2. BMI ≥30 kg\u002Fm2 or ≥27 kg\u002Fm2 with at least one obesity-related comorbidity\n3. Self-reported stable weight (no weight change \\>5%) for 6 months prior to the first study visit\n4. Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing laboratory\u002Fimaging\u002Fadditional tests, and completing diet counseling\n5. Willingness to NOT start a new anti-obesity medication for the following 12 months\n6. Residing within a reasonable distance from the investigator's office and able to travel to the investigator to complete routine follow-up visits\n7. Ability to give informed consent\n8. Women of childbearing potential (i.e., not post-menopausal, nor surgically sterilized) must agree to use adequate birth control methods\n\nExclusion Criteria:\n\n1. Known history of other chronic liver diseases (viral hepatitis, autoimmune hepatitis, drug-induced hepatitis, and genetic)\n2. Treatment with vitamin E (at doses ≥800 IU\u002Fday), pioglitazone, obeticholic acid, or resmetirom \\\u003C90 days before the first study visit\n3. History of foregut or gastrointestinal (GI) surgery (except uncomplicated fundoplication, cholecystectomy or appendectomy)\n4. Prior bariatric surgery\n5. Prior endoscopic sleeve gastroplasty\n6. Any inflammatory disease of the GI tract, including severe (LA Grade C or D) esophagitis, Barrett's esophagus with dysplasia, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease\n7. Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses\n8. Severe gastroesophageal reflux disease (GERD)\n9. A structural abnormality in the esophagus or pharynx, such as a stricture or diverticulum, that could impede passage of the endoscope.\n10. Achalasia or any other severe esophageal motility disorder\n11. Chronic abdominal pain\n12. Gastroparesis or intractable constipation\n13. Hepatic insufficiency or cirrhosis\n14. Severe coagulopathy\n15. Insulin-dependent diabetes (either type 1 or type 2) or a significant likelihood of requiring insulin treatment in the following 12 months or HgbA1C ≥ 12%\n16. Patients on an anti-platelet agent, anticoagulant agent or chronic\u002Froutine use of NSAIDs\n17. Patients on corticosteroids, immunosuppressants, or narcotics\n18. Patients on an anti-seizure or anti-arrhythmic medication\n19. Patients who are pregnant or breastfeeding\n20. Excessive alcohol consumption (\\>20 g per day for women; \\>30 g per day for men)\n21. Active smoking\n22. History of poorly controlled hypertension, coronary artery disease, congestive heart failure, cardiac arrhythmia\n23. History of respiratory diseases such as chronic obstructive pulmonary disease (COPD) requiring steroids, pneumonia, or cancer\n24. History of autoimmune connective tissue disorder such as lupus, scleroderma or immunocompromised disease\n25. History of active malignancy\n26. History of genetic or hormonal causes for obesity, such as Prader Willi syndrome\n27. History of endocrine disorders affecting weight, such as uncontrolled hypothyroidism\n28. Eating disorders, including night eating syndrome, bulimia, binge eating disorder or compulsive overeating\n29. Active psychological issues preventing participation in a lifestyle modification program as determined by a psychologist",{"count":178,"type":22},132,[95],"Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectrum, bariatric surgery has shown promise in the treatment of MASLD\u002Fmetabolic dysfunction-associated steatohepatitis (MASH) due to its efficacy in inducing weight loss. Nevertheless, its adoption has been hindered by the perceived invasiveness of surgery.\n\nOver the past decade, endoscopic sleeve gastroplasty (ESG) has gained recognition as a promising minimally-invasive approach to weight loss. The procedure involves utilizing a Food and Drug Administration (FDA)-authorized endoscopic suturing device to reduce the gastric volume by 70%. Studies reveal that ESG is associated with approximately 18.2% weight loss at one year after the procedure, with sustained results for at least 10 years. Nevertheless, the effect of ESG on MASH remains unknown.\n\nIn this study, the investigators will compare ESG + lifestyle modification versus lifestyle modification alone in treating histologic MASH. The study will randomize patients to one of two different treatment options: ESG + lifestyle modification or lifestyle modification alone.",[28,182,183,184,185,186,187,188,189,27,59,190,29,191,192,193,194,195,196],"Liver Diseases","Liver Fibrosis","Liver Fat","Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Dysfunction-Associated Steatohepatitis","MASLD","MASH","Weight Loss","Insulin Sensitivity\u002FResistance","Diabetes","Diabetes Mellitus, Type 2","NASH With Fibrosis","Non-Alcoholic Fatty Liver Disease","Non Alcoholic Fatty Liver","Non-alcoholic Steatohepatitis",[198,199,200,201,202,203,204,205,206,207,208,209,210],"Gut Hormones","Endoscopic Bariatric and Metabolic Therapy (EBMT)","Intragastric Balloon (IGB)","Endoscopic Suturing","Endoscopic Sleeve Gastroplasty (ESG)","Weight Management","Endoscopic Gastric Remodeling (EGR)","Endoscopic Bariatric Therapy (EBT)","Fatty Liver","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Non-Alcoholic Fatty Liver Disease (NAFLD)","Non-Alcoholic Steatohepatitis (NASH)","2026-06-23",{"date":213,"type":35},"2026-06-25",{"date":215,"type":35},"2025-06-24",{"date":217,"type":22},"2028-06",{"name":219,"class":42},"Pichamol Jirapinyo, MD, MPH",2,{"id":222,"slug":4,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":50,"enrollmentInfo":228,"targetDuration":4,"studyType":53,"phases":230,"briefSummary":231,"conditions":232,"keywords":235,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":249,"locationsCount":43},"100644025","NCT07664501","The Simplified Total-body Resistance Exercise for Muscular Hypertrophy for Diabetic Population (D-STORM)","The Simplified Total-body Resistance Exercise for Muscular Hypertrophy for Diabetic Population (D-STORM): Rationale and Study Protocol for a Randomized Controlled Trial","D-STORM","Inclusion Criteria:\n\n* Aged 18 to 65 years\n* Confirmed diagnosis of Type 2 Diabetes Mellitus\n* HbA1c between 6.5% and 13.0%\n* Not currently on insulin therapy\n* Has a primary care provider\n\nExclusion Criteria:\n\n* Age below 18 or above 65 years\n* Blood pressure 160\u002F100 mmHg or higher at screening\n* HbA1c below 6.5% or above 13.0%\n* Currently on insulin therapy\n* Pregnant or planning to become pregnant within the next 6 months\n* Serious medical conditions that would prevent safe participation in an exercise programme\n* Any physical or functional limitation that would prevent participation in resistance training\n* Underlying conditions that would not allow safe participation in the exercise intervention",{"count":229,"type":22},56,[95],"Type 2 diabetes is associated with progressive loss of muscle mass, which worsens blood sugar control and increases the risk of heart disease and disability. Resistance training (weight training) has been shown to build muscle and improve blood sugar levels, but most existing programmes use high intensities that are difficult for older or inactive people with diabetes to sustain.\n\nThis study tests a new resistance training programme called D-STORM (Simplified Total-body Resistance Exercise for Muscular Hypertrophy for Diabetic Population), which uses a lower, more manageable training load designed to be safe, tolerable, and effective for adults with Type 2 diabetes who are not on insulin.\n\nParticipants will be randomly assigned to either twice-weekly D-STORM training plus their usual diabetes care, or usual care alone, for 12 weeks. The main outcome measured is change in HbA1c (a blood test reflecting average blood sugar over 3 months). Body composition, walking capacity, blood pressure, heart rate, and quality of life will also be measured.",[233,234,27],"Type 2 Diabetes Mellitus (T2DM)","Sarcopenia",[236,237,238,239,240,241,242,243],"Type 2 diabetes mellitus","Resistance training","Muscular hypertrophy","Glycaemic control","HbA1c","Cardiometabolic outcomes","Randomised controlled trial","Minimal effective dose","2026-06-22",{"date":213,"type":35},{"date":247,"type":22},"2027-01-01",{"date":110,"type":22},{"name":250,"class":42},"Universiti Teknologi Mara",{"id":252,"slug":4,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":53,"phases":258,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":220},"100223978","NCT02193295","Reversal of Lipid-Induced Insulin Resistance","Inclusion Criteria:\n\n* Healthy, sedentary, non-smoking and not taking any medications other than birth control pills.\n* Hematocrit \\>35%\n* Subjects will have no systemic or organ disease including diabetes.\n* Subjects will have no history eating disorders.\n* Women must be using a form of birth control (sexual abstinence, birth control pills, Norplant, IUD or condoms) and will be studied between day 0 and 7 of their menstrual cycle.\n* Those who are taking birth control pills or have had a hysterectomy may be studied at any time.\n* Physical activity will be assessed using a standard questionnaire with an activity index cut off at 2.3.\n\nExclusion Criteria:\n\n* Any subject, who does not fit the inclusion criteria. Including history of eating disorders, any systemic and organ disease including diabetes.\n\nLactose intolerance Any blood count, clotting abnormalities HYpertriglyceridemeia (TG over 100 mg\u002FdL)\n\n* Hematocrit \\\u003C35%.\n* Women of childbearing potential, who are not using contraception (as mentioned above) or who are not abstinent.\n* Subjects who have a regular exercise regimen will not be enrolled.\n* Metal implants and\u002For body piercing, which cannot be removed before the MR studies.","90 Years",{"count":152,"type":22},[95],"The purpose of this study is to examine whether weight reduction decreases intramyocellular (IMCL) and hepatic lipid content, and improves insulin sensitivity of muscle and fat tissue in people who are insulin resistant and have a family history of type 2 diabetes.\n\nHepatic mitochondrial oxidation will be assesses using a 3 hour triple tracer study (D7 glucose, 3-13C lactate and 13C4 beta-hydroxybutyrate).",[27,261],"NAFLD",[263,264,265,266,267],"Weight Reduction","Caloric Restriction","Euglycemic Hyperinsulinemic Clamp","Magnetic Resonance Spectroscopy","PINTA","2026-06-17",{"date":244,"type":35},{"date":271,"type":35},"2002-10",{"date":273,"type":22},"2034-12",{"name":275,"class":42},"Yale University",{"id":277,"slug":4,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":50,"enrollmentInfo":281,"targetDuration":4,"studyType":53,"phases":283,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":43},"100641635","NCT07653464","Interplay of Central and Peripheral Vascular Effects of Insulin in Obesity","Inclusion Criteria:\n\n* 18 to 65 years of age\n\nIndividuals with obesity and comorbid IR\n\n* BMI 30-45 kg\u002Fm2\n* Waist circumference ≥102 cm (men) or ≥88 cm (women)\n* HOMA-IR ≥2.5\n\nHealthy normal weight adults\n\n* BMI 18-25 kg\u002Fm2\n* Waist circumference \\\u003C94 cm (men) and \\\u003C80 cm (women)\n* HOMA-IR \\\u003C2\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding\n* Unable to provide consent\n* Diabetes or polycystic ovarian syndrome\n* Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease, stroke\n* Nerve\u002Fneurologic disease\n* Uncontrolled hypertension (systolic blood pressure \\>180 mmHg and\u002For diastolic blood pressure \\>100 mmHg)\n* Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)\n* Current smoking, tobacco, nicotine use\n* Use of pharmacological therapy for weight loss\n* Body weight change \\>10% within the last 6 months\n* Adherence to \\>150 min\u002Fweek of moderate-to-vigorous physical activity\u002Fexercise\n* Participation in any other research study or medical procedure involving significant ionizing radiation exposure in the past 12 months\n* Claustrophobia\n* Non-MRI compatible metal implants",{"count":282,"type":22},64,[284],"EARLY_PHASE1","In the present study, we seek to determine the impact of obesity with insulin resistance on the neurovascular response to brain insulin stimulation.",[287,27],"Obesity (BMI>30)","2026-06-12",{"date":268,"type":35},{"date":291,"type":22},"2026-08",{"date":293,"type":22},"2032-06",{"name":295,"class":42},"University of Missouri-Columbia",{"id":297,"slug":4,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":305,"conditions":306,"keywords":311,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":4,"leadSponsor":322,"locationsCount":43},"100143840","NCT01143480","Study of the Effect of Innate on the Inflammatory Response to Endotoxin","Study of the Effect of Innate Immunity on the Inflammatory Response to Endotoxin","* INCLUSION CRITERIA:\n* Male or female 18 years of age or older\n* Participants must be able to understand and provide written informed consent to participate in the study\n* Participants must be able to travel to the CRU\n* Willing and able to fast after midnight the night prior to their study appointment.\n* Healthy participants as defined by the International Red Cross guidelines (Healthy means that an individual feels well and can perform normal activities. If the individual has a chronic condition such as diabetes or high blood pressure, healthy also means that they are being treated and the condition is under control).\n\nEXCLUSION CRITERIA:\n\n* Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 5 days prior to enrollment visit (e.g., Motrin, ibuprofen, naproxen, and Advil)\n* Use of acetaminophen (Tylenol) within 5 days prior to enrollment visit\n* Use of cholesterol lowering drugs (statins) within 30 days prior to enrollment visit (e.g., Zocor, Mevacor, Lipitor, and Crestor)\n* Use of immunosuppressants or other immune-modifying drugs \\[e.g., Rituxan, Humira, Enbrel, Cyclosporin (Neoral, Sandimmune, and SangCya), and Azathioprine (Imuran)\\], Monoclonal antibodies \\[e.g., infliximab (Remicade)\\], and corticosteroids (e.g., prednisone, prednisolone and dexamethasone)\n* Current treatment for cancer with chemotherapy or radiation\n* Confirmed or suspected immunosuppressive or immunodeficient condition\n* GI or respiratory Illness within 5 days prior to enrollment visit, including cold or allergies\n* Smoked tobacco, chewed tobacco or used electronic cigarettes within 2 weeks prior to enrollment visit (for participants who provide a urine specimen, this will be defined by urine cotinine \\>200 ng\u002FmL at visit)\n* Alcohol consumption greater than 2 standard drinks (1 standard drink contains 15 g of ethanol) per day within the last 24 hours prior to the enrollment visit\n* Body weight \\\u003C 50 kg (\\\u003C110 lbs)\n* Temperature \\> 37.6 C; blood pressure \\\u003C 90\u002F50 mm Hg or \\> 170\u002F95 mm Hg; pulse rate \\\u003C 50 or \\>100 beats\u002Fminute\n* Pregnant or suspected pregnancy\n* Chronic Kidney Disease\n\nThe PI may review medication use on a case by case basis and make a medical determination on the participant s eligibility. In these cases, the PI determination will be documented in the participant s chart.","100 Years",{"count":304,"type":22},725,"Background:\n\n\\- Innate immunity is the process by which white blood cells and other parts of the immune system sense and respond to potential infections by causing an inflammation. Researchers are interested in studying how the body responds to certain environmental factors, and whether the body s response can contribute to chronic illnesses or diseases such as asthma and certain types of cancers.\n\nObjectives:\n\n\\- To examine how specific genes and proteins in blood cells respond to environmental exposures.\n\nEligibility:\n\n\\- Healthy volunteers between 18 and 45 years of age.\n\nDesign:\n\n* The study will involve one visit of 45 to 60 minutes.\n* Participants will be screened with a brief physical examination and finger stick to determine if they are eligible to donate blood for the study, and will complete a questionnaire about any medications or other drugs (e.g., cigarettes) they may be taking.\n* Participants will provide a blood sample for research purposes.",[307,308,309,27,310],"Asthma","Atherosclerosis","Metabolic Syndrome","Cancer",[312,313,314,315,316],"Endotoxin","Innate Immunity","Natural History","Healthy Volunteer","HV","2026-06-10",{"date":319,"type":35},"2026-06-11",{"date":321,"type":35},"2012-07-30",{"name":323,"class":69},"National Institute of Environmental Health Sciences (NIEHS)",{"id":325,"slug":4,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":90,"enrollmentInfo":330,"targetDuration":4,"studyType":53,"phases":332,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":342,"locationsCount":43},"100424854","NCT04812314","Exercise Effects on Adipose Tissue Structure and Function","LG","Inclusion Criteria:\n\n* Age: 18-40\n* Body Mass Index: 27-45 kg\u002Fm2\n* No regularly planned exercise\u002Fphysical activity for at least 6 months\n* Women must have regularly occurring menses and must be premenopausal\n\nExclusion Criteria:\n\n* Evidence\u002Fhistory of cardiovascular or metabolic disease\n* Medications known to affect lipid or glucose metabolism, or inflammation\n* Weight instability ≥ ± 6 pounds in the last 3 months\n* Tobacco or e-cigarette users\n* Women must not be pregnant or actively lactating",{"count":331,"type":22},46,[95],"Participants will be randomized into one of two different experimental groups: 1) Exercise group and 2) No exercise (control group). Subject participation in the study will involve a series of metabolic tests before and after participants undergo a 10% weight loss program (with or without exercise training depending on group randomization). After completing this weight loss portion of the study, participants will then be required to adhere to a high calorie diet program to regain half of the weight the participant lost - followed by the same series of metabolic tests.",[28,309,29,27,189,335],"Weight Gain","2026-06-02",{"date":338,"type":35},"2026-06-04",{"date":340,"type":35},"2021-03-01",{"date":66,"type":22},{"name":41,"class":42},{"id":344,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":345,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":346,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":350,"leadSponsor":351,"locationsCount":43},"100516659",{"count":21,"type":22},[26,27,28,29,30],"2026-06-01",{"date":108,"type":35},{"date":37,"type":35},{"date":39,"type":22},{"name":41,"class":42},{"id":353,"slug":4,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":53,"phases":360,"briefSummary":361,"conditions":362,"keywords":366,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":43},"100610326","NCT07226128","The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV","A Randomized, Controlled Trial Assessing the Effects of Cognitive Behavioral Therapy to Prevent Worsening Insulin Resistance in Depressed, Virologically-Suppressed, Antiretroviral-Treated Adults With HIV","Inclusion Criteria:\n\n* HIV-1 infection, documented as listed clinically in the participant's electronic medical record by any of the following tests: (1) any licensed rapid HIV test, (2) HIV enzyme test kit at any time prior to study entry, (3) at least one detectable HIV-1 antigen, or (4) at least one detectable plasma HIV-1 RNA viral load.\n* Age ≥ 18 years.\n* Ongoing receipt of stable antiretroviral therapy of any kind for at least 180 days prior to Screening\n* Meets the depression definition for this trial:\n\n  * (1) repeat PHQ-9 ≥10100 result at the Screening Visit (suggesting moderate to severe depressive symptoms), AND\n  * (2) PHQ-9 depressive disorder diagnosis (2 or more of the 9 depressive symptoms, including depressed mood or anhedonia, present in the past 2 weeks), AND\n  * (3) functional impairment (using the tenth PHQ-9 item assessing social\u002Foccupational impairment), AND\n  * (4) no evidence that the direct physiological effects of a substance, medication, or medical condition clearly account for the depressive symptoms, AND\n  * (5) no bipolar or psychotic disorders\n\nNOTE: The use of antidepressant medications is not exclusionary.\n\n* HbA1c \\\u003C 6.5% at Screening\n* HIV-1 RNA level \\\u003C 75 copies\u002FmL at Screening\n\nNOTE: There are no CD4 cell count eligibility criteria for this trial.\n\nExclusion Criteria:\n\n* Inability to complete written, informed consent\n* Inability to read and understand English as seen on a computer screen\n* Diagnosed diabetes mellitus or any previously recorded HbA1c ≥6.5%\n* History of bipolar disorder or a psychotic disorder, including schizophrenia\n\nNOTE: Depressive disorders are not exclusionary.\n\n* Incarceration at the time of any study visit\n* Active suicidality at Entry, as determined by the patient's HIV provider or social worker following a positive response (1, 2, or 3) to PHQ-9 Item #9 and a positive response (yes) to one or more of the three questions (for Question #3, the previous attempt must be within the past 10 years) on the Patient Suicidality Form (see Appendix).\n* Diagnosed disease or process, besides HIV infection, associated with increased systemic inflammation (including, but not limited to, systemic lupus erythematosus, inflammatory bowel diseases, or other collagen vascular diseases).\n\nNOTE: Hepatitis B or C co-infections are NOT exclusionary, but treatment for hepatitis C cannot be provided during study participation\n\n* End stage renal disease requiring renal replacement therapy (dialysis, transplantation).\n* Known or suspected malignancy requiring systemic treatment within 180 days of the Entry Visit.\n\nNOTE: Localized treatment for skin cancers is not exclusionary.\n\n• Therapy for serious medical illnesses within 14 days prior to the Entry Visit\n\nNOTE: Therapy for serious medical illnesses that overlaps with a study visit will result in postponement of that study visit until the course of therapy is completed; postponement outside of the allowed study visit timeframe will result in study discontinuation.\n\n* Pregnancy or breastfeeding during the study.\n* Receipt of investigational agents, cytotoxic chemotherapy, systemic immunosuppressive therapies, systemic glucocorticoids (of any dose), or anabolic steroids at the Entry Visit\n\nNOTE: Physiologic testosterone replacement therapy or topical steroids is not exclusionary. Inhaled\u002Fnasal steroids are not exclusionary as long as the participant is not also receiving HIV protease inhibitors\n\nNOTE: Use of NSAIDS and aspirin are allowed\n\n• Active drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.",{"count":359,"type":22},150,[95],"The goal of this clinical trial is to learn if depression treatment improves insulin resistance, or how the body uses insulin to lower blood sugar, in people with HIV on HIV treatment. Researchers will compare an internet-based (online) depression treatment program called cognitive behavioral therapy with depression education. In the online group, participants will undergo 9 weekly treatment sessions. The education group will receive learning materials about depression and will be monitored every month. All participants will have 4 study visits over 12 months.",[363,364,27,365],"HIV","Depression in Adults","Cognitive Behavior Therapy",[367,368,132,369,370],"hiv","depression","diabetes","cognitive behavioral therapy","2026-05-31",{"date":336,"type":35},{"date":374,"type":35},"2026-04-10",{"date":376,"type":22},"2031-06-30",{"name":378,"class":42},"Indiana University",{"id":380,"slug":4,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":50,"enrollmentInfo":386,"targetDuration":4,"studyType":53,"phases":388,"briefSummary":390,"conditions":391,"keywords":394,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":402,"locationsCount":43},"100561599","NCT06592261","Graded Insulin Suppression Test P&F","Human Models of Selective Insulin Resistance: Graded Insulin Suppression Test (GIST) Pilot & Feasibility Study","GIST","Inclusion Criteria:\n\n* Body mass index of 18-25 and 30-45 kg\u002Fm2\n* Able to understand written and spoken English and\u002For Spanish\n* Fasting euinsulinemia (fasting serum insulin of 4-10 μU\u002FmL) for reference group or hyperinsulinemia (fasting serum insulin ≥ 13 μU\u002FmL) for hyperinsulinemic group on screening labs\n* Written informed consent (in English or Spanish) and any locally required authorization (e.g., Health Insurance Portability and Accountability Act) obtained from the participant prior to performing any protocol-related procedures, including screening evaluations.\n\nExclusion Criteria:\n\n* Unable to provide informed consent in English or Spanish\n* Unwillingness to use only bedpan or urinal to void or to refrain from non-emergent mobile device use during the GIST\n* Documented weight loss of ≥ 5% of baseline within the previous 6 months\n* Systolic blood pressure \\\u003C 90 mm Hg or \\> 160 mm Hg, and\u002For\n* Diastolic blood pressure \\\u003C 60 mm Hg or \\> 100 mm Hg\n* Abnormal resting heart rate: \\\u003C 60 or ≥ 110 bpm\n* Sinus brady or tachycardia that has been worked up and considered benign by the recruit's personal physician may be permitted at the PI's discretion\n* Abnormal screening electrocardiogram (or if on file, performed within previous 90 d):\n\n  * Non-sinus rhythm\n  * Heart conduction blocks\n  * Previously unknown ischaemic changes that persist on repeat EKG:\n  * ST elevations\n  * T-wave inversions in a vascular distribution\n* Hemoglobin A1c ≥ 5.7%, and\u002For\n* Fasting plasma glucose ≥ 100 mg\u002FdL\n* Positive qualitative β-hCG (i.e., pregnancy test) in women of childbearing potential\n* Positive urine drug screen, except for lawfully prescribed medications and\u002For marijuana, provided that participant agrees to refrain from marijuana use during the period that they refrain from alcohol.\n* Transaminases (AST or ALT) \\> 3.0 x the upper limit of normal\n* Total bilirubin \\> 1.25 x the upper limit of normal\n* Abnormal sodium, potassium, chloride, or bicarbonate levels that are considered potentially significant according to the clinical judgment of the PI.\n* Creatinine equating to estimated glomerular filtration rate \\\u003C 60 mL min-1 1.73 m-2\n* Hemoglobin \\\u003C 10 g\u002FdL or hematocrit \\\u003C 30%\n* Platelet count \\\u003C 100,000\u002FμL\n* Women currently pregnant, measured by serum and\u002For urine β-hCG\n* Women currently breastfeeding\n* History of having met any of the American Diabetes Association's definitions of prediabetic state during adulthood or diabetes mellitus (i.e., overt diabetes) at any time:\n\n  * Hemoglobin A1c ≥ 5.7%, or rapid rise in documented HbA1c values causing clinical concern for evolving insulin deficiency\n  * Plasma glucose ≥ 100 mg\u002FdL after 8-h fast\n  * Plasma glucose of ≥ 140 mg\u002FdL at 2 h after ingestion of a 75-g glucose load\n  * Random plasma glucose ≥ 200 mg\u002FdL associated with typical hyperglycemic symptoms, diabetic ketoacidosis, or hyperglycemic-hyperosmolar state\n* History of gestational diabetes mellitus within the previous 5 years\n* Use of most antidiabetic medications within the 30 days prior to screening\n\n  * Excluded: thiazolidinediones, sulfonylureas, meglitinides, DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, amylin mimetics, acarbose, insulin\n  * Metformin is acceptable provided that recruits meet all of the inclusion criteria at screening\n* Known, documented history, at the time of screening, of any of the following medical conditions:\n\n  * Pancreatic pathology, including but not limited to: Pancreatic neoplasia (unless appropriately evaluated and considered benign and not producing hormones), Chronic pancreatitis, History of acute pancreatitis within the past 5 years\n  * Cardiovascular diseases (N.B. uncomplicated hypertension is not exclusionary)\n  * Atherosclerotic cardiovascular disease\n  * Stable or unstable angina\n  * Myocardial infarction\n  * Ischaemic or hemorrhagic stroke\n  * Peripheral arterial disease (claudication)\n  * Use of dual antiplatelet therapy (aspirin + P2Y12 inhibitor)\n  * History of percutaneous coronary intervention\n  * Heart rhythm abnormalities (non-sinus)\n  * Congestive heart failure of any New York Heart Association class\n  * Severe valvular heart disease (e.g., aortic stenosis)\n  * Pulmonary hypertension\n* Chronic kidney disease, Stage 3 or higher (estimated glomerular filtration rate \\\u003C 60 mL\u002Fmin\u002F1.73 m2), of any cause\n* Advanced or severe liver disease, including but not limited to:\n\n  * Advanced liver fibrosis, as determined by non-invasive testing\n  * Cirrhosis of any etiology\n  * Autoimmune hepatitis or other rheumatologic disorder affecting the liver\n  * Biliopathy (e.g., progressive sclerosing cholangitis, primary biliary cholangitis)\n  * Hepatocellular carcinoma\n  * Infiltrative disorders (e.g., sarcoidosis, hemochromatosis, Wilson disease)\n* Gallstone disease, including:\n\n  * Biliary colic (active)\n  * History of acute cholecystitis not treated with cholecystectomy\n  * History of other gallstone complications (e.g., pancreatitis, cholangitis)\n* Chronic viral illness (N.B. diagnosis based only on medical history and not by laboratory confirmation)\n* Hepatitis B virus (HBV), unless previously successfully eradicated with antiviral drugs that have been discontinued for at least 30 d prior to screening\n* Hepatitis C virus (HCV) infection, unless previously successfully eradicated with antiviral drugs that have been discontinued for at least 30 d prior to screening\n* Human immunodeficiency virus (HIV) infection\n* Active seizure disorder (including controlled with antiepileptic drugs)\n* Psychiatric diseases causing functional impairment that:\n\n  * Are or have been decompensated within 1 year of screening, and\u002For\n  * Require use of anti-dopaminergic antipsychotic drugs associated with significant weight gain\u002Fmetabolic dysfunction (e.g., clozapine, olanzapine), monoamine oxidase inhibitors, tricyclic antidepressants, or lithium\n* Other endocrinopathies:\n\n  * Cushing syndrome (okay if considered in remission after treatment, provided that no exogenous corticosteroids or other ongoing treatment are required)\n  * Adrenal insufficiency\n  * Primary aldosteronism\n* Venous thromboembolic disease (deep vein thrombosis or pulmonary embolism) or any required use of therapeutic anticoagulation\n* Bleeding disorders, including due to anticoagulation, or significant anemia\n* Active malignancy, or hormonally active benign neoplasm, except allowances for:\n\n  * Non-melanoma skin cancer\n  * Differentiated thyroid cancer (AJCC Stage I only)\n* Clinical concern for increased risk of volume overload, including due to medications and\u002For heart\u002Fliver\u002Fkidney problems, as listed above\n* Clinical concern for increased risk of hypokalemia, including low potassium on screening labs (i.e., below lower limit of normal), use of certain medications, or any medical conditions listed above\n* Use of prescribed medications used for any of the indications in the preceding list of excluded conditions, or their use within 30 d prior to screening, except allowances for:\n\n  * Use of drugs prescribed for indications other than the exclusionary diagnoses\u002Fpurposes listed above (e.g., antiepileptic drugs used for non-seizure indications, ACEi\u002FARB used for uncomplicated hypertension rather than for congestive heart failure, etc.). Note, as above, that antidiabetic drugs except metformin within 30 d of screening are excluded.\n* Oral or parenteral corticosteroids (at greater than prednisone 5 mg daily, or equivalent) for more than 3 days within the previous 30 days; topical and inhaled formulations are permitted.\n* Beta blockers or non-dihydropyridine calcium channel blockers (verapamil or diltiazem)\n* History of certain weight-loss (bariatric) surgery, including:\n\n  * Roux-en-Y gastric bypass\n  * Biliopancreatic diversion\n  * Restrictive procedures (lap band, sleeve gastrectomy) performed within the past 6 months\n* Clinical concern for alcohol overuse, including recent documented history during screening and\u002For participant report of regularly consuming more than 2 drinks per day for males or 1 drink per day for females.\n* History of severe infection or ongoing febrile illness within 14 days of screening\n* Any other disease, condition, or laboratory value that, in the opinion of the investigator, would place the participant at an unacceptable risk and\u002For interfere with the analysis of study data.\n* Known allergy\u002Fhypersensitivity to any component of the medicinal product formulations, foods, IV infusion equipment, plastics, adhesive or silicone, history of infusion site reactions with IV administration of other medicines, or ongoing clinically important allergy\u002Fhypersensitivity as judged by the investigator.\n* Concurrent enrollment in another clinical study of any investigational drug therapy within 30 days prior to screening or within 5 half-lives of an investigational agent, whichever is longer.",{"count":387,"type":22},15,[389],"PHASE1","The goal of this study is to learn about how the hormone insulin controls blood sugar in a variety of people. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level. Participants will be asked to come in for a one-day study visit in which they will undergo a \"graded insulin suppression test\" (\"GIST\"). The GIST involves intravenous (into the vein) infusions of octreotide, a medication that turns off the body's own production of insulin, as well as replacement of insulin at two different levels (low and high), with or without replacement of glucagon, and glucose (sugar). The study investigators will check blood sugar levels every few minutes during the procedure to determine the effect of the two different insulin levels. This study will evaluate the GIST in both healthy volunteers and those at higher risk for type 2 diabetes.",[27,392,28,393],"Hyperinsulinemia","Healthy",[102,392,395,28],"Type 2 diabetes","2026-05-26",{"date":398,"type":35},"2026-05-28",{"date":400,"type":35},"2024-09-16",{"date":291,"type":22},{"name":403,"class":42},"Columbia University",{"id":405,"slug":4,"hasResults":11,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":53,"phases":412,"briefSummary":413,"conditions":414,"keywords":415,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":43},"100639892","NCT07606872","Validation of the Snouda Metabolic Score for Phenotyping and Guiding Reversal in Type 2 Diabetes","A Prospective Interventional Clinical Validation Study of the Snouda Metabolic Score (SMS) as a Phenotyping and Protocol-Targeting Instrument in Adults With Type 2 Diabetes Mellitus","SMS-VAL","Inclusion Criteria:\n\n* Confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) by a licensed healthcare provider\n* Age 18 years or older\n* HbA1c between 6.5% and 11.0% at baseline\n* Currently managed with lifestyle measures alone, or with oral glucose-lowering medications (metformin, SGLT2 inhibitors, DPP-4 inhibitors, or sulfonylureas)\n* Ability to access and use the diabetesreversal.io digital platform\n* Willingness to perform daily self-monitoring of blood glucose\n* Willingness to complete laboratory blood tests (Genesis Biomarker Panel) at baseline and Week 24 at own expense\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Type 1 Diabetes Mellitus or Latent Autoimmune Diabetes in Adults (LADA)\n* Currently pregnant or breastfeeding\n* Currently using insulin therapy\n* Currently using GLP-1 receptor agonists (e.g., semaglutide, liraglutide)\n* HbA1c greater than 11.0% at baseline\n* History of severe hypoglycemia requiring third-party assistance in the past 12 months\n* Active malignancy or receiving chemotherapy or radiation therapy\n* Severe renal impairment (eGFR less than 30 mL\u002Fmin\u002F1.73m²)\n* Severe hepatic impairment\n* Active eating disorder\n* Any condition that in the opinion of the investigator would make participation unsafe or interfere with study completion",{"count":359,"type":22},[95],"This study tests a new tool called the Snouda Metabolic Score (SMS) that helps doctors identify the specific metabolic problems driving Type 2 Diabetes in each individual patient. Instead of treating all diabetic patients the same way, the SMS classifies patients into one of several metabolic phenotypes - patterns of dysfunction across five body systems: insulin resistance, chronic inflammation, hormonal disruption, gut microbiome imbalance, and mitochondrial dysfunction.\n\nOnce classified, each participant follows a personalized 24-week lifestyle and nutritional protocol targeting their specific phenotype. The protocol includes dietary changes, structured exercise, targeted nutritional supplements, and optional intermittent fasting. Participants track their blood glucose daily and complete biomarker blood tests at the start and end of the study.\n\nThe main goal is to determine whether the SMS tool accurately identifies metabolic phenotypes and whether phenotype-matched protocols produce better outcomes than standard approaches. The study measures changes in HbA1c, fasting insulin, C-peptide, inflammation markers, and whether participants achieve Type 2 Diabetes remission - defined as HbA1c below 6.5% without glucose-lowering medication.\n\nThe study is conducted entirely online through the diabetesreversal.io platform. There are no clinic visits required. Participants must be adults aged 18 or older with a confirmed Type 2 Diabetes diagnosis and must not be pregnant or breastfeeding.",[233,27,309],[416,417,418,419,420,421,422,423,424,425],"Diabetes reversal","Metabolic phenotyping","Snouda Metabolic Score","Lifestyle intervention","HbA1c reduction","Intermittent fasting","Low-carbohydrate diet","Chronic inflammation","Mitochondrial dysfunction","Gut microbiome","2026-05-19",{"date":396,"type":35},{"date":429,"type":22},"2026-06",{"date":431,"type":22},"2027-03",{"name":433,"class":42},"Salah Snouda",{"id":435,"slug":4,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":439,"enrollmentInfo":440,"targetDuration":4,"studyType":53,"phases":442,"briefSummary":443,"conditions":444,"keywords":447,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":43},"100258681","NCT02646475","Metabolic Effects of Angiotensin-(1-7)","Inclusion Criteria:\n\n* Males and females of all races between 18 and 60 years of age\n* Obesity defined as body mass index between 30-40 kg\u002Fm2\n* Insulin resistance defined as homeostasis model assessment 2 insulin resistance (HOMA2-IR) score \\>2.2\n* Hypertension defined by two or more properly measured seated blood pressure readings \\>130\u002F85 mmHg, or by use of anti-hypertensive medications. This blood pressure cutoff will allow us to include subjects with pre-hypertension.\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breast-feeding\n* Current smokers or history of heavy smoking (\\>2 packs\u002Fday)\n* History of alcohol or drug abuse\n* Morbid obesity (BMI \\> 40 kg\u002Fm2)\n* Previous allergic reaction to study medications\n* Evidence of type I or type II diabetes (i.e. fasting glucose \\>126 mg\u002Fdl, use of anti-diabetic medications)\n* Cardiovascular disease other than hypertension such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy\n* History of serious cerebrovascular disease such as cerebral hemorrhage, stroke, or transient ischemic attack\n* History or presence of immunological or hematological disorders\n* Impaired hepatic function \\[aspartate amino transaminase (AST) and\u002For alanine amino transaminase (ALT) \\> 2.0 x upper limit of normal range\\]\n* Impaired renal function (serum creatinine \\>1.5 mg\u002Fdl)\n* Anemia (hemoglobin \\\u003C13.5 g\u002Fdl in males or \\\u003C12.5 g\u002Fdl in females)\n* Treatment with serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors\n* Treatment with phosphodiesterase 5 inhibitors\n* Treatment with anticoagulants\n* Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month)\n* Treatment with any investigational drug in the 1 month preceding the study\n* Inability to give, or withdraw, informed consent\n* Other factors which in the investigator's opinion would prevent the subject from completing the protocol (i.e., clinically significant abnormalities on clinical, mental examination or laboratory testing or inability to comply with protocol)","60 Years",{"count":441,"type":22},26,[389],"The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies. It is unclear if this peptide contributes to the regulation of metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance. The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.",[28,27,445,446],"Hypertension","Metabolic Cardiovascular Syndrome",[448,449,132,450],"renin-angiotensin system","angiotensin","blood pressure","2026-05-18",{"date":453,"type":35},"2026-05-22",{"date":455,"type":35},"2016-02",{"date":457,"type":22},"2029-12",{"name":459,"class":42},"Vanderbilt University",{"id":461,"slug":4,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":91,"enrollmentInfo":465,"targetDuration":4,"studyType":53,"phases":467,"briefSummary":468,"conditions":469,"keywords":472,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":43},"100526005","NCT06129110","Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling","Inclusion Criteria:\n\n* Generally healthy men and women aged 18-70\n* BMI between 30-40\n* Less than 1 hour of exercise per week\n* Women:\n\n  1. may be pre or post menopausal\n\nExclusion Criteria:\n\n* Type 1 or Type 2 diabetes\n* Thyroid disease\n* History of lung disease\n* Active use of nicotine\n* Severe plasma lipid disorders\n* Taking hormone replacement drugs, blood thinners, or thiazoladinediones\n* Women:\n\n  1. Currently going through menopause or peri-menopause\n  2. Pregnant or breastfeeding\n  3. History of Polycystic Ovary Syndrome",{"count":466,"type":22},70,[95],"The goal of this intervention study is to learn about how weight loss impacts molecular signaling of intermuscular adipose tissue (IMAT) in individuals with obesity. The main question it aims to answer is how inflammatory molecules secreted by IMAT promote muscle insulin resistance and inflammation, and how these same molecules are diminished after weight loss. Following screening visits involving body composition measures, blood testing, strength testing, and a thigh muscle biopsy, participants will go through a 12-week dietary intervention for weight loss. After 12 weeks, this will be followed by the same testing and biopsies that were completed before the intervention. Researchers will then compare outcomes of individuals who lost weight to individuals who did not lose weight.",[28,59,470,471,27],"Muscle Weakness","Adiposity",[473,474,189,475],"IMAT","Intermuscular Adipose Tissue","Diet","2026-05-13",{"date":478,"type":35},"2026-05-15",{"date":480,"type":35},"2024-01-31",{"date":482,"type":22},"2028-09-01",{"name":484,"class":42},"University of Colorado, Denver",{"id":486,"slug":4,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":490,"enrollmentInfo":491,"targetDuration":4,"studyType":53,"phases":493,"briefSummary":495,"conditions":496,"keywords":500,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":508,"leadSponsor":510,"locationsCount":43},"100630931","NCT07494084","Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance","Inclusion Criteria:\n\n1. Must be between 18-45 years old.\n2. Has a BMI of 18-25 kg\u002Fm2 stable weight over the previous 6 weeks.\n3. Is physically and psychologically healthy (incl. regular menstrual cycles in women, no clinical disorders and\u002For illnesses). Women will be studied during the follicular phase of their menstrual cycle.\n\n   Menstrual cycle criteria (using PMID 10941950) 18 to 25 years - Cycle variation ≤9 days 26 to 41 years - Cycle variation ≤7 days 42 to 45 years - Cycle variation ≤9 days\n4. No current medical or drug treatment (to include steroids or hormones of any type including contraceptives), as assessed by questionnaire.\n5. Has a negative pregnancy test (women), no clinically significant abnormalities in blood and urine, and free of traces of drugs.\n6. No history of clinically relevant psychiatric illness.\n7. No previous history of drug or alcohol abuse.\n8. Not a current smoker.\n9. No history of brain injury or of learning disability.\n10. No previous adverse reaction to sleep deprivation, jet lag, shift work or any of the drugs to be administered.\n11. Not vision or hearing impairment unless corrected back to normal.\n12. No endocrine disorder (no abnormal thyroid function tests; no abnormal morning blood cortisol; no primary gonadal disease as indicated by serum LH or FSH concentration \\> 10 or \\> 15 IU\u002FL, respectively; and no hyperprolactinemia indicated by prolactin \\> 25 μg\u002FL).\n13. No sleep or circadian disorder.\n14. Has good habitual sleep with regular bedtimes (between 6 and 10 hours in duration).\n15. Not extreme morning- nor extreme evening-type using Horne-Ostberg Morningness-Eveningness criteria.\n16. No travel across time zones within one month of entering the study.\n17. No shift work within three months of entering the study.\n18. No anemia (hematocrit \\\u003C38% in men, \\\u003C34% in women).\n19. No blood donation within the previous 8 weeks.\n20. No concurrent participation in another research study.","45 Years",{"count":492,"type":22},48,[494],"PHASE4","The purpose of this study is to examine the impact of timed cortisol release or differently timed cortisol rhythms on insulin resistance in both men and women undergoing sleep restriction. Chronic sleep loss is highly prevalent, affecting 1 in 3 adults in the US. Chronic sleep loss causes stress which induces insulin resistance and leads to obesity and type 2 diabetes. Many factors contribute to sleep loss including shift work, environmental disturbances, sleep\u002Fcircadian disorders and comorbid medical and mental health conditions. Sleep loss increases the stress hormone cortisol in the evening and decreases daytime testosterone. Examining these hormones in a controlled laboratory environment under different sleep schedules may help researchers find solutions for adults experiencing negative health consequences related to chronic sleep loss.",[497,498,27,499],"Shift Work Schedule","Circadian Rhythm","Circadian Misalignment",[501,132,502,503,504],"Shift work","sleep","circadian rhythm","type 2 diabetes","2026-05-12",{"date":478,"type":35},{"date":76,"type":22},{"date":509,"type":22},"2029-07",{"name":511,"class":42},"Washington State University",{"id":513,"slug":4,"hasResults":11,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":11,"sex":17,"minAge":519,"maxAge":520,"enrollmentInfo":521,"targetDuration":4,"studyType":53,"phases":522,"briefSummary":523,"conditions":524,"keywords":530,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":220},"100438049","NCT04984226","Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD","Randomized Cross-over Trial of Sodium Bicarbonate on Muscle Mitochondrial Energetics and Physical Endurance in Chronic Kidney Disease and Metabolic Acidosis","Senergy-CKD","Inclusion Criteria:\n\n* Moderate-severe CKD determined by eGFR \\\u003C50ml\u002Fmin per 1.73m2 by CKD EPI equation on at least 2 consecutive occasions.\n* Metabolic acidosis defined as bicarbonate level\\\u003C24 on two consecutive occasions. Bicarbonate level of 24 or less allowed if eGFR\\\u003C=45ml\u002Fmin per 1.73m2\n* Age 21 to 85 years old\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* Poorly controlled diabetes (HgbA1c\\>10%)\n* History of persistent hyperkalemia (K\\>5.4)\n* History of persistent hypokalemia (K\\\u003C3.3)\n* Uncontrolled blood pressure (\\>170\u002F100)\n* Chronic treatment with renal replacement therapy\n* History of aortic dissection or severe valvular heart disease\n* Exercise induced angina\n* Uncontrolled cardiac dysrhythmia\n* Oxygen dependent chronic obstructive pulmonary disease (COPD)\n* Symptomatic claudication\n* End stage liver disease\n* Mobility disability defined as inability to walk without human assistance\n* Dementia or psychosis\n* Patients who cannot consent\n* Active use of intraveneous drugs\n* Non-english speaking\n* History of transplant\n* Implants that prohibit MRI measurements or trauma involving metal fragments\n* Pacemaker\n* Expectation to start dialysis during the course of study.\n* Women who are breastfeeding, pregnant, or are wanting to become pregnant\n* Any condition which in the judgement of the clinical investigator places the participant at risk from participation in the study.\n\nExclusion criteria for optional muscle biopsy\n\n* Drugs- anticoagulants or antiplatelets:\n\n  * Anticoagulants, any 1 (coumadin, rivaroxaban, apixaban, dabigatran, edoxaban)\n  * Antiplatelets, any 2 (aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticragrelor, ticlopidine, vorapaxar)\n* Platelet count \\\u003C100,000\n* International normalized ratio (INR)\\>1.4","21 Years","85 Years",{"count":122,"type":22},[55],"Skeletal muscle metabolic health is critical for mobility and an underrecognized target of metabolic acidosis in chronic kidney disease. Impaired muscle mitochondrial metabolism underlies poor physical endurance increasing the risk of mobility disability. The proposed project will use precise in vivo tools to study the pathophysiology of poor physical endurance in a clinical trial treating metabolic acidosis among persons living with chronic kidney disease.",[525,526,527,528,27,529,191],"Chronic Kidney Diseases","Metabolic Acidosis","Fatigue","Physical Endurance","Mitochondrial Energetics",[531,532,102],"Metabolic acidosis","Chronic kidney disease","2026-05-04",{"date":535,"type":35},"2026-05-06",{"date":537,"type":35},"2023-09-08",{"date":539,"type":22},"2026-12-31",{"name":541,"class":42},"University of California, Davis",{"id":543,"slug":4,"hasResults":11,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":50,"enrollmentInfo":549,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":551,"conditions":552,"keywords":553,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":43},"100275170","NCT02861781","Collection of Human Metabolic Tissues","Study of New Determinants of Type 2 Diabetes in Severe Obesity","COMET","Inclusion Criteria:\n\n1. Written informed consent\n2. Age 18 - 65 years inclusive at surgery\n3. IMC \\> 35\n4. Subject qualified for bariatric surgery (sleeve gastrectomy or gastric bypass)\n5. Specific criteria :\n\n   * Type 2 diabetes group (D) (90 patients) : type 2 diabetes according to ADA criteria\n   * Insulin resistance non diabetes group (IR) (80 patients) : HOMA-IR criteria ≥ 3\n   * Insulin Sensitivity non diabetes group (N) (100 patients) : N1.HOMA-IR criteria \\\u003C 3\n\nNon inclusion Criteria:\n\n1. Vulnerability according to article L1121-6 of the Public Health Code\n2. Protected adult or unability to give consent according to article L1121-8 of the Public Health Code\n3. Unability to understand the design and aims of the study or to communicate with the investigator\n4. Non affiliation to a social security system\n5. Prior bariatric surgery (except lap-band procedure)\n6. Serologic profile indicating hepatitis B, hepatitis C or HIV infection\n7. Inflammatory, infectious or autoimmune disease (current or in the previous 3 month)\n8. Malignancies within 5 years prior to inclusion or not considered as treated curatively\n9. Concomitant use of steroids or NSAI or use in the 8 days before surgery\n10. alcohol abuse\u002Faddiction\n11. Anticipated poor compliance to study procedures\n12. Other type of diabetes than type 2\n\nExclusion Criteria :\n\n1. Cancelled bariatric surgery\n2. Tissue collection not possible during the bariatric surgery",{"count":550,"type":22},270,"This project aims at identifying new determinants of type 2 diabetes in severe obesity. To do so, a biological collection, including tissues of interest in the field of metabolism, will be collected during bariatric surgery in obese patients. Three different groups of metabolic status of patients, corresponding to different stages of evolution of the disease, will be constituted: type 2 diabetes, insulin resistance, insulin sensitivity.\n\nThe main objective is to compare, between these 3 groups of patients, several biological processes that may be involved in the pathophysiology of type 2 diabetes and disorders associated with obesity, including:\n\n* Abnormalities of the transcriptome, proteome, metabolome in all target tissues (plasma, serum, muscle, subcutaneous and visceral adipose tissue, omental artery, liver)\n* Identification of metabolic signatures, protein and miRNA in plasma\n* Immunoinflammatory response in adipose tissue\n* Polymorphisms SNP from whole blood\n* Histological analysis of tissue sections This main objective will be studied on samples taken at the time of surgery Secondary objectives will be to study the changes in metabolites, proteins and miRNA in plasma level 3 and 12 months after the completion of surgery, according to the initial metabolic state.",[28,27,192],[554],"Bariatric surgery",{"date":556,"type":35},"2026-05-08",{"date":558,"type":35},"2016-02-02",{"date":560,"type":22},"2028-09",{"name":562,"class":42},"University Hospital, Montpellier",{"id":564,"slug":4,"hasResults":11,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":11,"sex":570,"minAge":19,"maxAge":490,"enrollmentInfo":571,"targetDuration":573,"studyType":23,"phases":4,"briefSummary":574,"conditions":575,"keywords":587,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":43},"100636441","NCT07565727","Cardiometabolic Disease and Substrate Metabolism","Cardiometabolic Disease, Substrate Metabolism, and Abnormal Placental Pathology: a Multimodal Maternal-Fetal Study","CAP","Inclusion Criteria:\n\n* Age 18-45\n* Any pre-pregnancy BMI\n* At least one high risk OR one moderate risk factor for pre-eclampsia based on ACOG and USPSTF guidelines\n* Willingness to adhere to aspirin therapy\n* Willingness to undergo 2h OGTT for serum collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n* Gestational age at enrollment \\\u003C18 weeks\n* Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n* Type 1 Diabetes Mellitus\n* Current gestational diabetes mellitus\n* Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n* Thrombophilia\n* Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n* Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n* Current or recent use of steroids\n* Current use of prophylactic or therapeutic anticoagulation\n* Medical contraindication to aspirin therapy\n* Molar pregnancy\n* Renal disease\n* Inability or unwillingness to give informed consent\n* Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators","FEMALE",{"count":572,"type":22},50,"9 Months","This study's primary purpose is to determine the potential relationship between cardiometabolic disease, specifically insulin resistance (HOMA-IR), and maternal lipid oxidation.",[576,577,578,579,580,581,582,27,583,584,585,586],"Preeclampsia","Gestational Diabetes Mellitus (GDM)","Preeclampsia (PE)","Preeclampsia (PE) Risk","Gestational Diabetes","Gestational Diabetes Mellitus in Pregnancy","Cardiometabolic Diseases","Placental Dysfunction","Pregnancy","Pregnancy Complications","Gestational Complications",[588,589,576,580,102,590,591,592,593],"Cardiometabolic disease","Substrate metabolism","HOMA-IR","Lipid oxidation","Placental dysfunction","Chorangiosis","2026-04-27",{"date":533,"type":35},{"date":597,"type":35},"2025-12-10",{"date":599,"type":22},"2027-08",{"name":601,"class":42},"University of Tennessee Graduate School of Medicine",{"id":603,"slug":4,"hasResults":11,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":608,"enrollmentInfo":609,"targetDuration":4,"studyType":53,"phases":611,"briefSummary":612,"conditions":613,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":618,"leadSponsor":620,"locationsCount":4},"100618589","NCT07333586","Insomnia and Insulin Resistance","Insomnia, Metabolic Syndrome and Insulin Resistance","Inclusion Criteria:\n\nages 18-50 y BMI 28-45 kg\u002Fm2 Score on the Insomnia Severity Index ≥15.\n\nExclusion Criteria:\n\ncontraindications for CBT-I (mania or seizure disorder) symptoms requiring immediate attention (e.g., psychosis, suicide intent) report illicit substance use on a monthly basis (e.g., cocaine, opioids) receiving behavioral treatment for insomnia overt cardiovascular disease overt renal disease thyroid disease cancer pregnant dieting using GLP-1 agonists taking exogenous insulin","50 Years",{"count":610,"type":22},20,[95],"Insomnia symptoms are linked to metabolic syndrome (MetS), which includes abnormal glucose metabolism, insulin resistance (IR), and incidence of diabetes. Chronic sleep deficit is a major predictor of disease and early mortality. Further, insomnia is the most common sleep disorder in the United States. The recommended first line of treatment for insomnia is Cognitive Behavioral Therapy for Insomnia (CBT-I). CBT-I is a multidimensional treatment that targets the thoughts and behaviors that perpetuate insomnia symptoms over time. This study will explore CBT-I effects on MetS outcomes (ie. blood pressure, triglycerides, etc.) and provide preliminary evidence that CBT-I impacts IR and fasting glucose concentrations within this population.\n\n20 subjects with insomnia will be recruited. They will be randomly assigned to either CBT-i or sleep hygiene. The intervention is 5 wks. Pre and post intervention, the investigator will have participants fill out a number of questionnaires, a daily sleep diary, 2 weeks of actigraphy measuring sleep and physical activity and there will be a single blood draw at the beginning and the end of the study.",[614,27],"Insomnia",{"date":616,"type":35},"2026-04-28",{"date":347,"type":22},{"date":619,"type":22},"2027-06-01",{"name":295,"class":42},{"id":622,"slug":4,"hasResults":11,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":626,"eligibilityCriteria":627,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":628,"targetDuration":629,"studyType":23,"phases":4,"briefSummary":630,"conditions":631,"keywords":634,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":43},"100512271","NCT05950282","Determinants of Insulin Sensitivity by Age, Sex, Race\u002FEthnicity, BMI, and PCOS Diagnosis","Measuring Fasting Insulin and HOMA-IR by Age, Sex, Race\u002FEthnicity, BMI, and PCOS Diagnosis","DAISY","Inclusion Criteria Age: Participants aged 18+ years Sex: Both males and females Race\u002FEthnicity: Participants from diverse racial and ethnic backgrounds BMI: Participants across a range of body mass index (BMI) values PCOS Diagnosis: Participants with and without a confirmed diagnosis of PCOS based on established diagnostic criteria\n\nParticipants must have completed metabolic testing within one month prior to enrollment, including:\n\n* Fasting insulin\n* Hemoglobin A1c (A1c)\n* Complete lipid panel\n* Triglycerides Laboratory testing must be completed through a healthcare provider, an independent laboratory, or by using an Insara Insulin Testing Kit Laboratory values must be obtained following a minimum 8-hour fast Participants must have complete laboratory data for all required measures\n\nExclusion Criteria Age: Participants below 18 years Sex: None. Both males and females are included Race\u002FEthnicity: None. Participants from all racial and ethnic backgrounds are included Endocrine Disorders: Participants with other endocrine disorders affecting insulin levels (e.g., insulin-secreting tumors) Significant recent weight change: Loss of more than 5% of body weight within the previous month Pregnancy or breastfeeding Acute illness or infection within the past 2 weeks Use of medications known to significantly affect insulin or glucose metabolism will be recorded and accounted for in analysis",{"count":359,"type":22},"1 Year","The study aims to investigate the relationship between fasting insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) across various demographic factors, including age, sex, race\u002Fethnicity, BMI, and polycystic ovary syndrome (PCOS) diagnosis. By analyzing these variables, the study seeks to identify potential variations in insulin levels, which could provide valuable insights into the impact of different factors on metabolic health and the development of insulin-related conditions.",[27,632,633,28,309],"Polycystic Ovary Syndrome","Hyperinsulinism",[635,392,27,309,28,26],"PCOS",{"date":637,"type":35},"2026-05-01",{"date":639,"type":35},"2024-02-01",{"date":641,"type":22},"2027-12",{"name":643,"class":42},"Ali Chappell",{"id":645,"slug":4,"hasResults":11,"nctId":646,"briefTitle":647,"officialTitle":647,"acronym":648,"eligibilityCriteria":649,"healthyVolunteers":16,"sex":570,"minAge":650,"maxAge":651,"enrollmentInfo":652,"targetDuration":4,"studyType":53,"phases":654,"briefSummary":655,"conditions":656,"keywords":662,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":665,"lastUpdatePostDateStruct":666,"startDateStruct":668,"completionDateStruct":670,"leadSponsor":672,"locationsCount":220},"100480983","NCT05543083","Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes","CBTeX","Inclusion Criteria:\n\n* Female\n* Age 12-17 years\n* Body Mass Index (BMI)\\>= 85 for age and sex\n* Type 2 Diabetes (T2D) first-or second-degree relative\n* Center for Epidemiologic Studies Depression Scale (CES-D) total score \\>=21\n\nExclusion Criteria:\n\n* T2D\u002F Type 1 Diabetes (T1D) or any major medical condition (e.g. cardiovascular, renal) that would prohibit the ability to participate in exercise training\n* Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) conduct disorder, substance abuse\u002F dependence, obsessive compulsive disorder, panic attacks, post-traumatic stress disorder, anorexia\u002Fbulimia, \\& schizophrenia\n* Insulin sensitizers, weight loss medications \\& chronic steroids\n* Structured weight loss treatment or bariatric surgery\n* Pregnancy, nursing","12 Years","17 Years",{"count":653,"type":22},300,[95],"The investigators are doing this study to learn more about how to prevent type 2 diabetes in teenage girls. The purpose of this study is to find out if taking part in a cognitive-behavioral therapy group, exercise training group, or a combination of cognitive-behavioral therapy and exercise training groups, decreases stress, improves mood, increases physical activity and physical fitness, and decreases insulin resistance among teenagers at risk for diabetes.",[27,657,658,659,660,633,661,29],"Depression","Depressive Disorder","Mood Disorders","Mental Disorder in Adolescence","Glucose Metabolism Disorders",[663,664],"Adolescent Type 2 Diabetes Prevention","Exercise Training","2026-04-17",{"date":667,"type":35},"2026-04-22",{"date":669,"type":35},"2023-06-02",{"date":671,"type":22},"2029-03-31",{"name":673,"class":42},"Colorado State University",""]